Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

Prothena Corporation plc (PRTA) announced that Bristol Myers (BMY) has in-licensed exclusive global rights to PRX019, a potential treatment option for certain neurodegenerative diseases. PRX019 is the second candidate that has been in-licensed by Bristol Myers under its existing collaboration agreement with PRTA. Prothena anticipates initiating an early-stage study of the candidate by the end of 2024. Bristol Myers' decision to exercise its option for the exclusive global license for PRX019 follows the FDA ...